BOULDER, CO — November 13, 2025 — Leads & Copy — Reliefacyn® Advanced Itch-Burn-Rash-Pain Relief Hydrogel, a product of Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), has earned the National Rosacea Society (NRS) Seal of Acceptance.
The NRS Seal of Acceptance program helps people with rosacea find suitable skin care and cosmetic products. The seal identifies gentle products unlikely to irritate sensitive skin affected by rosacea. To earn the seal, products must undergo clinical testing and expert evaluation.
Sonoma Pharmaceuticals CEO Amy Trombly said the company is honored to receive the recognition from the NRS. She noted that Reliefacyn has previously received the National Eczema Association Seal of Acceptance and the National Psoriasis Foundation Seal of Recognition.
Trombly said the NRS recognition highlights the versatility of Sonoma’s Microcyn-based products and the company’s commitment to providing safe and effective skincare solutions for people living with chronic skin conditions such as eczema, psoriasis and rosacea.
Sonoma Pharmaceuticals develops and produces stabilized hypochlorous acid (HOCl) products for various applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. The company’s products have been clinically proven to reduce itch, pain, scarring and irritation without damaging healthy tissue.
In-vitro and clinical studies show that HOCl can safely manage skin abrasions, lacerations, minor irritations, cuts and intact skin. Sonoma’s products are sold directly or via partners in over 55 countries.
The company is headquartered in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. Its European marketing and sales operations are based in Roermond, Netherlands. Sonoma actively seeks new distribution partners. For partnership opportunities, contact busdev@sonomapharma.com.
Forward-Looking Statements: This press release contains forward-looking statements about Sonoma Pharmaceuticals’ commercial and technology progress and future financial performance. These statements are subject to risks and uncertainties that could cause actual results to vary. Factors include regulatory changes, insufficient scientific data, challenges to patents, market size and penetration.
Sonoma Pharmaceuticals™, Microcyn® and Reliefacyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc.
Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.
ir@sonomapharma.com
Follow Sonoma Pharmaceuticals on LinkedIn, Instagram, and Facebook.
Source: Sonoma Pharmaceuticals, Inc.
